Company intelligence / Profile preview

Iscador AG

Arlesheim, Basel-Land, Switzerlandiscador.com ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Iscador AG manufactures ISCADOR®, a fermented aqueous extract of white mistletoe used as an adjunctive therapy in cancer treatment. The product has been prescribed for nearly a century as part of integrative oncology approaches. Clinical studies suggest benefits in quality of life, immune modulation, and possible survival improvement when used alongside conventional therapies. Ongoing clinical trials include Phase 2 studies in relapsed osteosarcoma patients post-metastasectomy.

Therapeutic areas: Oncology
Modalities: Plant extracts (specifically fermented mistletoe extract)
Industry: Biotech

Drug pipeline

7 assets

Iscador P

6 more assets in the full pipeline.

Partnerships

No major pharmaceutical partnerships identified; historically distributed by Weleda AG until autumn 2015. Now independently markets its products.

Beyond the preview

Go deeper on Iscador AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iscador AG.